Article · 16 Sep 2026
Conference abstract
Pharmacogenomics of Alziemer�s Disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Recent advances in genomic medicine can contribute to accelerating our understanding on pathogenesis of dementia, improving diagnostic accuracy with the introduction of novel biomarkers, and personalizing therapeutics with the incorporation of pharmacogenetic and pharmacogenomic procedures to drug development and clinical practice. Most neurodegenerative disorders, including Alzheimer�s disease(AD),share some common features, such as a genomic background in which hundreds of genes(more than 200 genes) might be involved, genome-environment interactions, complex pathogenic pathways, poor therapeutic outcomes and chronic disability. The AD population exhibits a higher genetic variation rate than the control population with absolute and relative genetic variations of 40-60% and 0,85- 1,89%, respectively. AD patients also differ in their genomic architecture from patients with other forms of dementia. Functional genomic studies in AD revealed that age of onset, brain atrophy, cerebrovascular hemodynamics, brain bioelectrical activity, cognitive decline, apoptosis are associated with AD- related genes. Pioneering pharmacogenomics studies also demonstrated that the therapeutic response in AD is genotype-specific, with apolipoprotein E(APOE 4/4 carriers the worst responders to conventional treatments. Pharmacogenetic and pharmacogenomic factors may account for 60-90% of drug variability in drug disposition and pharmacodynamics. The main aim of a cost-effective treatment is to halt disease progression via a modification of the functional cascade involving AD genomics, transcriptomics, proteomics and metabolomics. Unfortunately, the drugs available for the treatment of dementia are not cost-effective. The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutica Analytica Acta.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Jerzy Leszek”
